Urokinase Down-Regulation by Aprotinin in Rabbit Corneal Cells After Photorefractive Keratectomy

REFERENCES

• Csutak A, Tőzsér J, Békési L, et al. Plasminogen activator activity in tears after excimer laser photorefractive keratectomy. Invest Ophthalmol Vis Sci 2000;41:3743–3747.
   PubMed Web of Science ®Google Scholar
• Csutak A, Silver DM, Tőzsér J, et al. Plasminogen activator activity and inhibition in rabbit tears after photorefractive keratectomy. Exp Eye Res 2003;77:675–680.
   PubMedGoogle Scholar
• Lottemberg R, Sjak-Shie N, Fazleabas AT, et al. Aprotinin inhibits urokinase but not tissue-type plasminogen activator. Thromb Res 1988;49:549–556.
   PubMedGoogle Scholar
• Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 1983;33:479–494.
   PubMed Web of Science ®Google Scholar
• Salonen EM, Tervo T, Törma E, et al. Plasmin in tear fluid of patients with corneal ulcers: Basis for new therapy. Acta Ophthalmol 1987;65:3–12.
   PubMed Web of Science ®Google Scholar
• Gundorowa RA, Bordjugowa GG, Choroschilowa-Maslewa IP, et al. Treatment of eye burns with a polyvalent proteolytic inhibitor. Klin Histochem 1989;92:441–448.
   PubMedGoogle Scholar
• Boisjoly HM, Sun R, Giasson M, et al. Topical fibronectin and aprotinin for keratectomy wound healing in rabbits. Arch Ophthalmol 1990;108:1758–1763.
   PubMedGoogle Scholar
• Zieske JD, Bukusoglu G. Effect of protease inhibitors on corneal epithelial migration. Invest Ophthalmol Vis Sci 1991;32:2073–2078.
   PubMedGoogle Scholar
• Tripathi RC, Tripathi BJ, Park JK. Localization of urokinase-type plasminogen activator in human eyes: An immunocytochemical study. Exp Eye Res 1990;51:545–552.
   PubMedGoogle Scholar
• Tőzsér J, Berta A.Urokinase-type plasminogen activator in rabbit tears. Comparison with human tears. Exp Eye Res 1990;51:33–37.
   PubMedGoogle Scholar
• Thorig L, Wijngaards G, Van Haeringen NJ. Immunological characterization and possible origin of plasminogen activator in human tear fluid. Ophthalmic Res 1983;15:268–276.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Sueishi K. Fibrinolytic activity and species of plasminogen activator in human tears. Exp Eye Res 1988;46:131–137.
   PubMedGoogle Scholar
• Berta A, Tőzsér J, Holly FJ.Determination of plasminogen activator activities in normal and pathological human tears. The significance of tear plasminogen activators in the inflammatory and traumatic lesions of the cornea and conjunctiva. Acta Ophthalmol (Copenh) 1990;68:508–514.
   PubMedGoogle Scholar
• Barlati S, Marchina E, Quaranta CA, et al. Analysis of fibronectin, plasminogen activators and plasminogen in tear fluid as markers of corneal damage and repair. Exp Eye Res 1990;51:1–9.
   PubMedGoogle Scholar
• Lohmann CP, Marshall J. Plasmin- and plasminogen-activator inhibitors after excimer laser photorefractive keratectomy: New concept in prevention of postoperative myopic regression and haze. Refract Corneal Surg 1993;9:300–302.
   PubMedGoogle Scholar
• Watanabe M, Yano W, Kondo S, et al. Up-regulation of urokinase-type plasminogen activator in corneal epithelial cells induced by wounding. Invest Ophthalmol Vis Sci 2003;44:3332–3338.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Mishima H, Nishida T, et al. Role of urokinase type plasminogen activator (u-PA) in corneal epithelial migration. Thromb Haemost 1993;69:387–391.
   PubMed Web of Science ®Google Scholar
• Berman M. The pathogenesis of corneal epithelial defects. Acta Ophthalmol Suppl 1989;192:55–64.
   PubMedGoogle Scholar
• Hayashi K, Berman M, Smith D, et al. Pathogenesis of corneal epithelial defects: Role of plasminogen activator. Curr Eye Res 1991;10:381–398.
   PubMed Web of Science ®Google Scholar
• Sappino AP, Huarte J, Vassalli JD, et al. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest 1991;87:962–970.
   PubMed Web of Science ®Google Scholar
• Vassalli JD, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 1987;214:187–191.
   PubMed Web of Science ®Google Scholar
• Zhou L, Beuerman RW, Huang L, et al. Proteomic analysis of rabbit tear fluid: Defensin levels after an experimental corneal wound are correlated to wound closure. Proteomics 2007;7:3194–3206.
   PubMed Web of Science ®Google Scholar
• Berman M, Leary R, Gage J. Evidence for a role of the plasminogen activator–plasmin system in corneal ulceration. Invest Ophthalmol Vis Sci 1980;19:1204–1221.
   PubMed Web of Science ®Google Scholar
• Csutak A, Silver DM, Tözsér J, et al. Urokinase-type plasminogen activator to prevent haze after photorefractive keratectomy, and pregnancy as a risk factor for haze in rabbits. Invest Ophthalmol Vis Sci 2004;45:1329–1333.
   PubMedGoogle Scholar
• Csutak A, Silver DM, Tőzsér J, et al. Plasminogen activator inhibitor in human tears after laser refractive surgery. J Cataract Refract Surg 2008;34:897–901.
   PubMedGoogle Scholar
• Suzuki M, Kobayashi H, Fujie M, et al. Kunitz-type protease inhibitor bikunin disrupts phorbol ester-induced oligomerization of CD44 variant isoforms containing epitope v9 and subsequently suppresses expression of urokinase-type plasminogen activator in human chondrosarcoma cells. J Biol Chem 2002;277:8022–8032.
   PubMedGoogle Scholar
• Shetty S, Pendurthi UR, Halady PK, et al. Urokinase induces its own expression in Beas2B lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002;283:L319–L328.
   PubMedGoogle Scholar
• Chesnokova, NB, Kuznetsova, TP, Sosulina NE. Pharmacokinetics of polyvalent proteinase inhibitor (aprotinin) in eye tissues. Doc Ophthalmol 1994;85:275–280.
   PubMedGoogle Scholar
• Dunbar SD, Ornstein DL, Zacharski LR. Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin. Expert Opin Investig Drugs 2000;9:2085–2092.
   PubMed Web of Science ®Google Scholar